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Background: The study evaluated the efficacy of beclomethasone dipropionate/formoterol fumarate (BDP/FF)
extrafine combination versus fluticasone propionate/salmeterol (FP/S) combination in COPD patients.
Methods: The trial was a 12-week multicentre, randomised, double-blind, double dummy study; 419 patients with
moderate/severe COPD were randomised to BDP/FF 200/12 μg or FP/S 500/50 μg twice daily. The primary objective
was to demonstrate the equivalence between treatments in terms of Transition Dyspnoea Index (TDI) score and the
superiority of BDP/FF in terms of change from pre-dose in the first 30 minutes in forced expiratory volume in the
first second (FEV1). Secondary endpoints included lung function, symptom scores, symptom-free days and use of
rescue medication, St. George’s Respiratory Questionnaire, six minute walking test and COPD exacerbations.
Results: BDP/FF was equivalent to FP/S in terms of TDI score and superior in terms of FEV1 change from pre-dose
(p < 0.001). There were no significant differences between treatments in secondary outcome measures, confirming
overall comparability in terms of efficacy and tolerability. Moreover, a clinically relevant improvement (>4 units) in
SGRQ was detected in the BDP/FF group only.
Conclusion: BDP/FF extrafine combination provides COPD patients with an equivalent improvement of dyspnoea
and a faster bronchodilation in comparison to FP/S.
Trial registration: ClinicalTrials.gov: NCT01245569Background
Chronic obstructive pulmonary disease (COPD) is a pro-
gressive disease estimated to become the third leading
cause of death and the fifth cause of morbidity world-
wide by 2020 [1]. It is characterised by progressive air-
flow limitation which is not fully reversible and is
associated with an enhanced pulmonary inflammatory
response. Disease severity is determined by the degree of
airflow limitation, the frequency of exacerbations, the se-
verity of symptoms and the presence of co-morbidities.
Current medical interventions are now increasingly fo-
cused on providing relief to symptoms that majorly* Correspondence: DSingh@meu.org.uk
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reproduction in any medium, provided the orimpact on quality of life, such as dyspnoea and de-
creased exercise capacity [1]. One particular focus is the
effect of treatments in the morning, when COPD symp-
toms and patients’ ability to perform daily activities
appear to be worst [2].
International guidelines recommend that treatment
follows a stepwise approach, with the early introduction
of bronchodilators for all patients with COPD, and the
later addition of an inhaled corticosteroid (ICS) limited
to patients with severe airflow limitation and/or frequent
exacerbations [1]. Treatment with a long-acting β2 agon-
ist (LABA) and ICS can be administered through single
combination inhalers. ICS/LABA combinations reduce
the frequency of exacerbations and improve lung func-
tion to a greater degree than the monocomponents
alone [3], and there are beneficial molecular interactionstd. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly credited.
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ness [4,5]. However, high ICS doses have been associated
with an increased risk of pneumonia [6-8]. Hence, the
dose–response relationship of ICS in COPD is currently
a matter of debate [1], especially since head-to-head
studies comparing different dosages of ICS in COPD are
still lacking [9].
The ICS/LABA combination beclomethasone dipropi-
onate 100 μg plus formoterol fumarate 6 μg (BDP/FF) is
an extrafine formulation that optimises small particle de-
position throughout the bronchial tree, including the
small airways; It is licensed for use in asthma, and is
being developed as a treatment for COPD [10,11]. FF is
a LABA with a rapid onset of action [12], while in con-
trast the LABA salmeterol has a slow onset of action.
Consequently, a potential advantage of FF over salmeterol
when used in combination inhalers is that the morning
dose can more rapidly improve lung function, and so pro-
vide greater benefits for COPD patients who suffer with
morning symptoms [13,14].
The aim of the FUTURE trial was to compare the effi-
cacy of two fixed combination therapies that deliver dif-
ferent ICS doses; extrafine BDP/FF versus fluticasone /
salmeterol (FP/S) where the daily ICS doses are 400 μg
and 1000 μg / day respectively. We measured symptoms
and lung function after 12 weeks to compare the efficacy
of these treatments. Furthermore, we also investigated
the acute bronchodilator effects in the morning to study




This study was carried out in 76 outpatient respira-
tory clinics throughout Europe and included patients
aged ≥ 40 years with a diagnosis of moderate to severe
COPD. Inclusion criteria were: smoking history ≥ 10 pack
years; regular bronchodilator use in the previous 2 months;
post-bronchodilator forced expiratory volume measured
in the first second (FEV1) < 60% of predicted; post-
bronchodilator FEV1/forced vital capacity (FVC) < 0.7; an
increase in FEV1 ≥ 5% from baseline following administra-
tion of 400 μg of salbutamol; a Baseline Dyspnoea Index
(BDI) focal score ≤ 10 at the screening and randomisation,
and a history of ≤ one COPD exacerbation treated with
antibiotics or systemic corticosteroids in the previous
12 months. Patients were excluded if they had been diag-
nosed with asthma, other respiratory disorders, or any
other clinically relevant condition that could have inter-
fered with the evaluation of results.
The study was performed in accordance with the prin-
ciples of the Declaration of Helsinki and with the Good
Clinical Practice guidelines recommended by the Inter-
national Conference on Harmonization of TechnicalRequirements. The protocol was approved by the Institu-
tional Review Board of each centre (a list is shown in
Additional file 1), and informed written consent was
obtained from each participant prior to study entry.
Study design
This was a randomised, double-blind, double-dummy,
2-arm parallel group study. After a screening visit,
patients entered a 2-week run-in period, where they re-
ceived inhaled ipratropium bromide (Atrovent® Inhaler
CFC-Free 20 μg) as maintentance treatment adminis-
tered 4 times / day. Patients were then randomised to a
12-week treatment period with either extrafine BDP/FF
100/6 μg in a hydrofluoralkane pressurised metered dose
inhaler (pMDI; FOSTER®, Chiesi Farmaceutici, Parma,
Italy) or FP/S 500/50 μg, in a dry-powder inhaler (DPI;
Seretide®, Accuhaler® GlaxoSmithKline, Middlesex, UK).
Randomization was performed according to a pre-
determined balanced-block, computer generated, random-
isation list stratified by country. BDP/FF was administered
as two puffs twice daily (daily dose 400 μg BDP/24 μg FF),
while FP/S was administered as one inhalation twice
daily (daily dose 1000 μg FP/100 μg S). Clinic visits
were performed at monthly intervals. Inhaled rescue
salbutamol use was permitted during the whole study
period (including run-in), but no other COPD medications
were permitted.
Protocol outcome measures
The two co-primary efficacy variables were Transition
Dyspnoea Index (TDI) score at the end of the study
(week 12), and Area Under the Curve (AUC0-30min) stan-
dardized by time of change from pre-dose in FEV1 after
drug inhalation during the morning of baseline visit. In
order to demonstrate the equivalence between BDP/FF
and FP/S in terms of TDI, dyspnoea was assessed at
baseline with the Baseline Dyspnoea Index (BDI)
score and by TDI score at week 12 [15]. Pulmonary
function tests (PFTs) were performed, in accordance
with ATS/ERS standards [16], at the screening visit
before (pre-bronchodilator) and after (post-bronchodilator)
salbutamol inhalation and at each clinic visit. At baseline
and week 12, PFTs were performed before study drug in-
halation (pre-dose) and then 5, 15 and 30 minutes after
(post-dose). At week 4 and 8, spirometry was per-
formed at pre-dose only. PFTs were all performed at
least 12 hours after the previous evening dose and
6 hours after previous salbutamol use. Each site was pro-
vided with the same spirometer FlowScreen® CT that dir-
ectly transferred PFTs values to the e-CRF.
A diary card was used each morning at home to
record COPD symptom scores, the number of inhala-
tions of study medication (run-in medication included)
and salbutamol use; the diary card is shown in Additional
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ity to perform usual daily activities, breathlessness, night
waking caused by respiratory symptoms, breathlessness on
rising, cough and sputum production; each was assigned a
score ranging from 0 (no symptoms) to 3 (worst), giving a
maximum total score of 18 / day; this questionnaire has
been used previously in a COPD clinical trial [11], but has
not been formally validated for this purpose.
Occurrence of COPD exacerbations and adverse
events were evaluated by the Investigator at all visits,
by diary review and asking the patient. Health status was
assessed using the St. George’s Respiratory Questionnaire
(SGRQ) [17,18] at baseline and at week 12. All patient-
reported outcomes were gathered pre-dose in the morn-
ing. The six-minute walking test (6MWT) was carried out
following ATS guidelines [19] at pre-dose and post-dose,
both at baseline and week 12.
Statistics
Data are expressed as mean and standard deviation
(SD), unless otherwise specified. The study was powered
to detect a mean difference between treatments of
0.080 L in the AUC0-30min standardized by time of
change from pre-dose in FEV1 at baseline visit, as-
suming a SD of 0.16 L and using a two-sample t-test
with two-sided significance level of 0.05 (further details
are in Additional file 1). Superiority for AUC0-30min was
demonstrated if the two-sided 95% confidence interval
(CI) for the adjusted mean difference between the two
drugs lied entirely above 0. Equivalence in TDI score was
demonstrated if the two-sided 95% CI for the adjusted
mean difference lied entirely within the equivalence mar-
gins fixed at ± 1, assuming the true mean difference in
TDI score between treatments is 0 and the standard devi-
ation is 2.7.
For all parameters, the analysis of covariance, with
treatment and country as factors, and baseline value
(pre-dose at randomisation visit) as a linear covariate,
was applied. All analyses were performed with SAS™
System (SAS Institute Inc, Cary, NC), version 9.2.
Statistical significance was set at 0.05 two tailed, and
all analyses were performed on the intention-to-treat
population (ITT). Imputation of missing data was
completed following last observation carried forward
method for post-baseline data. According to the current
indication for ICS/LABA use in COPD [1], a pre-defined
analysis was performed in patients with FEV1 < 50% of
predicted for all efficacy variables.
Results
Patients
Of the 675 patients screened, 419 were randomized and
373 completed the study (Figure 1). The reasons for
screening failure are provided in Additional file 1. Thefirst patient was enrolled in April 2011 and the last com-
pleted the trial in March 2012. The most common
causes of study discontinuation were development of
exclusion criteria (3.8%) and protocol violations (2.9%).
The frequency of withdrawal for adverse events was
similar in the BDP/FF and FP/S groups (0.9% and 1.4%
respectively).
The characteristics of the patients at baseline is summa-
rized in Table 1, (see Additional file 1 for characteristics of
the subgroup with FEV1 < 50% predicted). Overall, approxi-
mately 73% of patients randomised were using ICS at
screening. Patient compliance evaluated from diary cards
was >98% in both groups.
Primary endpoints
At week 12, the TDI score had improved in both groups
(Figure 2); the adjusted means (95% CI) were 1.32 (0.87-
1.77) for BDP/FF and 1.15 (0.70-1.60) for FP/S; the mean
difference between treatments was 0.17 and the 95% CI
for the difference (−0.39 to 0.72; p = 0.56) was entirely
within the ±1 equivalence margins, with no statistically
significant difference between treatments. Ninety-three
patients (44.1%) in the BDP/FF group and 89 (43.0%) in
the FP/S group had a TDI score ≥ 1 (p = 0.92). The
equivalence between BDP/FF and FP/S was also demon-
strated in patients with FEV1% predicted <50%, where
the difference between groups was −0.06 (−0.78 to 0.66;
p = 0.87); 43 patients (36.1%) in the BDP/FF group and
50 (41.0%) in the FP/S group (p = 0.51) showed a TDI
score ≥ 1.
The AUC0-30min adjusted means (95% CI) were 0.18 L
(0.16-0.19) and 0.11 L (0.09-0.12) for the BDP/FF and
FP/S groups respectively, with a statistically signifi-
cant difference between groups of 0.07 L (0.05-0.10;
p < 0.001). Similarly, in patients with FEV1 < 50% of pre-
dicted the difference between groups was 0.08 L (0.05-
0.10, p < 0.001). Figure 3 shows that FEV1 improved
significantly at 5, 15 and 30 minutes post-dose in both
treatment groups (p < 0.001 at all-time points). The im-
provements were significantly greater after BDP/FF com-
pared to FP/S group at all timepoints (p < 0.001); the
mean (95% CI) differences at 5, 15 and 30 minutes were
0.08 (0.06-0.11); 0.07 (0.04-0.10) and 0.07 (0.04-0.10),
respectively.
Secondary endpoints
There was an increase in the pre-dose morning FEV1 at
week 12 compared to baseline in both treatments groups,
with no difference between treatments; see Table 2
(the analysis of patients with FEV1 < 50% predicted is
in Additional file 1).
FEV1 post-dose at week 12 improved significantly in
both treatment groups (p < 0.001 at all time-points;
Figure 3b), with a significantly greater effect observed
Figure 1 Patient flow. SF: screening failure due to ineligibility; CW: consent withdrawn; EC: development of exclusion criteria; AEs: adverse
events; LF: lost to follow-up; PV: protocol violations; OR: other reasons; TF: treatment failure. For some AEs (1 in the BDP/FF group and 2 in the
FP/S group) the cause of withdrawn was reported as EC, as stated in the Study Termination Form of the e-CRF.
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point). The mean differences (95% CI) between groups at
5, 15 and 30 minutes were 0.09 (0.07-0.11); 0.08 (0.05-0.10)
and 0.07 (0.05-0.10), respectively. Similar changes were
seen in patients with FEV1 predicted <50%; see Additional
file 1 for figure and statistical analysis.
COPD total symptom score decreased significantly
(p < 0.001) from baseline in both treatment groups at all
intermediate visits (data not shown) and at the end of the
study (see Additional file 1), with no difference between
treatments (see Table 2). The number of symptom-free
days increased significantly in both groups (p < 0.001),
with no difference between groups. There were simi-
lar findings in patients with FEV1 predicted <50% (see
Additional file 1).
The SGRQ total score, and the single domain scores,
decreased significantly from baseline to week 12 (p < 0.001)
(see Figure 4 and Additional file 1), with no significant dif-
ference between groups (Table 2). The pre-dose distance
walked in 6 minutes increased significantly in both treat-
ment groups with respect to baseline in both groups (see
Additional file 1). The difference between groups in the
change from baseline to week 12 was 9.39 metres
(95% CI: −9.63 to 28.41), and was not statistically signifi-
cant (Table 2). There were similar findings in patients
with FEV1 predicted <50%; see Additional file 1.Six (2.8%) patients in the BDP/FF treatment group and
4 (1.9%) in the FP/S group reported exacerbations, with
no difference between groups. The majority of exacerba-
tions occurred in patients with FEV1% < 50% of pre-
dicted; 5 (4.2%) patients in the BDP/FF group and 3
(2.5%) in the FP/S group.
Tolerability
Treatment-emergent serious adverse events (SAEs)
were significantly lower (p = 0.024) in the BDP/FF group
(4 patients, 1.9%) than in the FP/S group (13 patients,
6.3%). Pneumonia was reported in 3 patients (1.4%)
treated with FP/S and none treated with BDP/FF. Wors-
ening of COPD was reported in 2 (1.0%) patients treated
with FP/S and none treated with BDP/FF. Three patients
(1.4%) treated with BDP/FF and 5 treated with FP/S
(2.4%) discontinued the study due to adverse events (AEs).
There were no differences between groups in terms of vital
signs and ECG. Further details of adverse events are in
Additional file 1.
Discussion
This is the first head-to-head study comparing extrafine
BDP/FF with one of the most commonly used drugs
for COPD patients (FP/S), evaluating different ICS dos-
ages in fixed combination therapies. The TDI findings
Table 1 Demographics and baseline characteristics
BDP/FF FP/S
(N = 211) (N = 207)
Gender:
Male (%) 155 (73.5) 143 (69.1)
Female (%) 56 (26.5) 64 (30.9)
Age, years 63.8 (8.2) 63.7 (8.6)
BMI, kg/m2 26.16 (5.37) 27.02 (5.60)
Smoking habits:
Ex-smokers (%) 106 (50.2) 121 (58.5)
Current smokers (%) 105 (49.8) 86 (41.5)
No. of pack years 40.1 (20.4) 41.9 (23.0)
Previous treatments* (%)
Long-acting anticholinergic 139 (65.9) 140 (63.6)
LABA 51 (24.2) 44 (21.3)
ICS/LABA fixed combination 119 (56.4) 126 (60.9)
ICS 36 (17.1) 28 (13.5)
Pre-dose FEV1, litre 1.13 (0.40) 1.10 (0.36)
Pre-bronchodilator FEV1, litre
† 1.13 (0.33) 1.10 (0.30)
Post- bronchodilator FEV1, litre
† 1.31 (0.32) 1.29 (0.33)
Post- bronchodilator FEV1/FVC (%)
† 44.2 (9.7) 44.4 (9.8)
Post- bronchodilator FEV1
(% predicted normal)†
46.5 (9.6) 46.4 (9.8)
FEV1 post-bronchodilator change (%)
† 17.5 (11.0) 17.8 (11.0)
BDI score 6.1 (1.8) 6.1 (1.7)
SGRQ score 47.0 (16.7) 45.2 (16.5)
pre-dose 6MWT, metres 352 (106) 364 (109)
Symptom score 6.27 (3.57) 6.05 (3.72)
Symptom-free days (%) 7.55 (20.14) 7.21 (20.59)
Rescue medication-free days (%) 44.27 (42.10) 39.69 (39.86)
Patients with no exacerbations in the
previous year
116 (55.0%) 108 (52.2%)
All values are presented as mean (SD) or absolute number (%).
BDP/FF, beclomethasone dipropionate/formoterol fumarate; FP/S, fluticasone
propionate/salmeterol; BMI, body mass index; LABA, long-acting β2-agonist;
ICS, inhaled corticosteroids; FEV1, forced expiratory volume in the first second,
FVC, Forced Vital Capacity; BDI, basal dyspnoea index; SGRQ, St. George’s
respiratory questionnaire; 6MWT, 6 minutes walking test.
*patients can have more than one treatment. †Evaluated in the screening visit
(before and after salbutamol inhalation).
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BDP/FF combination compared to FP/S provides equiva-
lent symptom control, while the lung function findings
for AUC0-30min confirmed a faster onset of action of the
formoterol component compared to salmeterol.
The co-primary endpoint measurement of TDI assessed
changes in breathlessness that may have been due ei-
ther to differences in the ICS or LABA in the combin-
ation inhalers. We have demonstrated that the BDP/FF
combination with a lower ICS dose compared to theFP/S combination was associated with similar improve-
ments in symptom control. This may be due to the ef-
fects of the LABAs within these combination inhalers
[3,20] as well as to better distribution of extrafine parti-
cles of ICS. There are differences between these LABAs,
as we have demonstrated for the AUC0-30min, and others
have also reported in COPD studies of combination in-
halers [13,14]. It is difficult in head to head studies of
combination inhalers to be sure which effect is due to the
LABA or ICS. Nevertheless, the similar results for both
combinations suggests that the ICS dose used does not
influence symptom control.
A major goal of COPD pharmacotherapy is to relieve
subjective symptoms [1]. The equivalence of the TDI
score demonstrates that extrafine BDP/FF impacts
COPD symptoms to the same degree as FP/S, despite
using a lower ICS dose. A 1 unit change in TDI is recog-
nised as a clinically meaningful difference, so we chose
this magnitude of change for the equivalence limits
[21,22]. We also analysed the number of patients who
improved by >1, and again did not find any difference
between the treatments.
Early morning symptoms are very common in COPD
patients [2,23]. Rapid bronchodilation improves physical
exercise tolerance upon wakening, which is one of the
most common COPD-associated symptoms [23]. The
faster onset of action of formoterol compared to salme-
terol has been clearly demonstrated in asthma [24], but
results in COPD patients are less consistent, as previ-
ous studies comparing these drugs in COPD patients
have often involved relatively small study populations
[25,26], or provided uncertain results [27,28]. However,
larger COPD studies have shown that the fixed com-
bination of budesonide/formoterol has a faster onset
of action in the morning compared to FP/S [13,14].
We now also demonstrate this finding for extrafine
BDP/FF, and show that this is present after the first
dose and maintained after 12 weeks treatment. The
benefit achieved after the first dose may be import-
ant in providing patients with reassurance regarding
drug effectiveness, which will likely improve medica-
tion compliance [29]. The maintained presence of a
faster onset of action in the morning observed up to
12 weeks may benefit COPD patients who chronically
suffer with early morning symptoms.
The secondary efficacy endpoint measurements, which
included changes in FEV1 pre-dose, SGRQ and 6MWT,
also showed no difference between treatments. Both
treatments improved SGRQ scores and 6MWT com-
pared to baseline, although only the mean SGRQ change
from baseline for BDP/FF reached the clinical meaning-
ful threshold (> 4 units). A large randomized controlled
COPD study [11] reported similar efficacy of the BDP/
FF extrafine combination to the higher ICS dose in the
Figure 2 Transition dyspnoea index (TDI) score at week 12. BDP/FF, beclomethasone dipropionate/formoterol fumarate; FP/S, fluticasone
propionate/salmeterol. There were no differences (p > 0.05) between BDP/FF and FP/S. The threshold for clinical relevance only applies to the TDI
total domain score.
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48 weeks. The important role of long acting bronchodi-
lators in reducing hyperinflation and thus improving ex-
ercise tolerance is well established, and these 6MWT
results are likely to reflect similarities in the degree of
bronchodilation and benefit on hyperinflation achieved
by the LABAs [30].Figure 3 Change in FEV1. (a) Change from pre-dose in FEV1 (L)
measured at baseline; (b) Change from pre-dose in FEV1 (L) measured
at week 12. FEV1, forced expiratory volume in the first second; BDP/FF,
beclomethasone dipropionate/formoterol fumarate; FP/S, fluticasone
propionate/salmeterol. p < 0.001 at each time point compared to
baseline pre-dose for both treatments and at each visit. ***p < 0.001
between treatments.The effectiveness of the lower ICS dose in BDP/FF
may be due to the extra-fine formulation that allows
homogeneous distribution of the two drugs throughout
the bronchial tree [31] entailing a greater efficacy per
microgram of ICS, in agreement with previous studies
on asthma [32-34]. The extra-fine BDP/FF formulation
allows the treatment of both large and small airways; the
latter are particularly relevant in COPD pathophysiology
[35]. Peripheral airway obstruction causes progressive
“air trapping” during exercise and consequent limitation
of exercise capacity in COPD patients [1]. The effect of
BDP/FF extrafine combination on small airways in COPD
has been demonstrated in terms of reduction of air trap-
ping measured as reduction in residual volume [36] and
increase in FVC [11].
The use of a combination with a lower ICS dose can
be of particular relevance in COPD patients since side
effects of ICS are dose-dependent [7] and are linked to
an increased risk of pneumonia, as highlighted in the
TORCH study [20]. Moreover, the approved dosage of
FP/S in COPD patients is 500 μg/50 μg twice daily in
the EU [37], while in the US only a lower dose (250 μg/
50 μg twice daily) was approved on the basis of clinical
trial results [38-40], and importantly because an efficacy
advantage of the higher strength had not been demon-
strated [41].
One limitation of this study may be the lack of a third
arm as a control group (e.g. LABA alone). However, the
superiority of both extrafine BDP/FF and FP/S over pla-
cebo and the monocomponents have been previously
demonstrated [11,20].
The COPD patients enrolled were required to have
FEV1 < 60% of predicted, as ICS/LABA combination
therapies are most commonly used in patients with
Table 2 Comparisons between the groups at week 12: adjusted values from ANCOVA analysis
BDP/FF FP/S Between groups
p value(N = 211) (N = 207)
Pre-dose morning FEV1, litre 0.08 (0.04 to 0.11) 0.06 (0.03 to 0.10) 0.58
Pre-dose morning FVC, litre 0.06 (−0.00 to 0.13) 0.05 (−0.01 to 0.12) 0.82
SGRQ score −5.92 (−7.75 to −4.08) −3.80 (−5.70 to −1.90) 0.08
SGRQ decrease from baseline > 4, patients (%) 95 (45.0) 75 (36.2) 0.16
6MWTa, meters 31.62 (15.18 to 48.06) 22.23 (6.30 to 38.16) 0.33
6MWT changea > 37 meters, patients (%) 39 (18.8) 34 (16.4) 0.60
Symptom scoreb −1.21 (−1.55 to −0.87) −1.00 (−1.35 to −0.65) 0.36
Breathlessness on risingb −0.26 (−0.35 to −0.18) −0.24 (−0.32 to −0.16) 0.65
Symptom-free daysc,% 4.60 (1.79 to 7.41) 5.88 (2.99 to 8.76) 0.50
Use of rescue medicationb, puffs −0.60 (−0.78 to −0.42) −0.63 (−0.81 to −0.45) 0.80
Rescue medication-free daysc,% 13.50 (9.39 to 17.61) 13.11 (8.89 to 17.32) 0.89
All values are presented as mean (95% CI) or absolute number (%).
BDP/FF, beclomethasone dipropionate/formoterol fumarate; FP/S, fluticasone propionate/salmeterol; FEV1, forced expiratory volume in the first second; FVC,
Forced Vital Capacity; SGRQ, St. George’s respiratory questionnaire 6MWT, 6 minutes walking test.
achange from pre-dose at randomization visit to pre-dose at the end of treatment.
bmean of the last two weeks (week 11–12).
coverall results were considered (entire treatment period).
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S matches this pulmonary function criteria. ICS/LABA
combinations are licensed for use in patients with
greater than or equal to one exacerbation per year. We
excluded patients with greater than one exacerbation
per year, in order to avoid a high drop out rate due to
exacerbations during the trial period. Patients were
required to demonstrate an increase in FEV1 ≥ 5% after
salbutamol at screening; this ensured that the pa-
tients had some degree of therapeutic response to
beta-agonist treatment. We considered this to be a
useful inclusion criteria when comparing long acting
beta agonists [13,28]. It should be noted that 73.5% of
the patients included in this study were using ICSFigure 4 Change in SGRQ. (a) Change from baseline in SGRQ total score;
with FEV1 < 50% of predicted normal value. SGRQ, St. George Respiratory Q
fumarate; FP/S, fluticasone propionate/salmeterol. p > 0.05 (not significant)
the FEV1 < 50% of predicted normal value population. P values shown refebefore entry into the study; the population enrolled
therefore was highly representative of patients who use
ICS in real life.
Conclusions
The present study shows that, despite its lower ICS dose,
extrafine BDP/FF (200/12 μg twice daily) is equivalent in
improving dyspnoea and has a faster onset of action with
respect to FP/S (500/50 μg twice daily) in patients with
COPD. The benefits for patients treated with extrafine
BDP/FF compared to FP/S may be twofold: first, the
lower concern related to ICS dosage and second, a faster
onset of bronchodilation, which can reduce morning
symptoms.(b) Change from baseline in SGRQ total score in the ITT population
uestionnaire; BDP/FF, beclomethasone dipropionate/formoterol
for differences between BDP/FF and FP/S both in the general and in
r to change from baseline: ***p < 0.001, and *p = 0.01.
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